ストックスクリーナーアプリを入手
0.2808
17.54%
-0.0608
前日終値:
$0.3416
開ける：
$0.341
24時間の取引高:
1.84M
Relative Volume:
1.36
時価総額：
$19.69M
収益：
-
当期純損益:
$-41.95M
株価収益率:
-0.3383
EPS:
-0.83
ネットキャッシュフロー:
$-38.34M
1週間 パフォーマンス:
-21.88%
1か月 パフォーマンス:
-10.14%
6か月 パフォーマンス:
-47.00%
1年 パフォーマンス:
-92.45%
1日の値動き範囲:
$0.2728
$0.341
1週間の範囲:
$0.2728
$0.3747
52週間の値動き範囲:
$0.221
$4.33
Elevation Oncology Inc Stock (ELEV) Company Profile
ELEV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELEV
Elevation Oncology Inc
|
0.2816 | 19.69M | 0 | -41.95M | -38.34M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.18 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.19 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.89 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.36 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.47 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-24 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2025-03-21 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-21 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-03-21 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-01-03 | 開始されました | William Blair | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2024-03-01 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-05-30 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2021-12-23 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Elevation Oncology Inc (ELEV) 最新ニュース
Elevation Oncology Advances Novel HER3 ADC Program While Securing Cash Runway Through 2026 - Stock Titan
Elevation Oncology, Inc. SEC 10-Q Report - TradingView
Allogene's Q1 Earnings In Line With Estimates, Sales Nil - Barchart.com
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates - Yahoo Finance
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% On '25 View Cut - Barchart.com
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut - Yahoo Finance
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y - The Globe and Mail
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook - Zacks Investment Research
JPMorgan Chase & Co. Purchases 119,041 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Geode Capital Management LLC Grows Stock Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Renaissance Technologies LLC Sells 182,673 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
William Blair Reaffirms Their Buy Rating on Elevation Oncology (ELEV) - The Globe and Mail
Elevation Oncology Inc Inc. (ELEV) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Elevation Oncology Inc (ELEV)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX
Elevation Oncology Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Elevation Oncology reveals promising ADC data for solid tumors - Investing.com
Elevation Oncology reveals promising ADC data for solid tumors By Investing.com - Investing.com India
Breakthrough Cancer Drug EO-1022 Outperforms Existing HER3 Therapies in Stability and Anti-Tumor Activity - Stock Titan
Adversity is less terrifying than hope: Elevation Oncology Inc (ELEV) - Sete News
Elevation Oncology (ELEV) to Release Quarterly Earnings on Thursday - Defense World
Market Recap Check: Elevation Oncology Inc (ELEV)’s Negative Finish at 0.37, Up/Down -1.61 - DWinneX
Potential Price Increase for Elevation Oncology Inc (ELEV) After Recent Insider Activity - knoxdaily.com
Are Elevation Oncology Inc’shares a good deal? - uspostnews.com
Elevation Oncology Inc (ELEV): What Makes The Stock Good? - Marketing Sentinel
GSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotech - BioPharma Dive
Elevation mulls strategic alternatives, including closure, amid activist pressure - PharmaLive
Elevation Mulls Strategic Alternatives, Including Closure, Amid Activist Pressure - BioSpace
Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down - insights.citeline.com
Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) PT at $3.39 - Defense World
Rare NRG1 Fusion Market to Reach New Heights in Growth by 2034, - openPR.com
Fierce Biotech Layoff Tracker 2025: Pfizer sells site, cuts staff; Opthea reduces workforce by 65% - Fierce Biotech
Trading Day Review: Elevation Oncology Inc (ELEV) Loses Momentum, Closing at 0.25 - DWinneX
Elevation Oncology opts for early term loan repayment By Investing.com - Investing.com South Africa
Elevation Oncology opts for early term loan repayment - Investing.com
Elevation Oncology IncTo Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022SEC Filing - MarketScreener
Elevation Oncology stock hits 52-week low at $0.24 By Investing.com - Investing.com Canada
Virtu Financial LLC Takes $36,000 Position in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology’s Chief Medical Officer Steps Down - TipRanks
What is Elevation Oncology Inc (ELEV) Stock Return on Shareholders’ Capital? - Sete News
A closer look at Elevation Oncology Inc (ELEV)’s stock price trends - uspostnews.com
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Longview News-Journal
Breakthrough Cancer Drug Shows Promise: First Look at EO-1022 Data for Breast and Lung Cancer - Stock Titan
Elevation Oncology (NASDAQ:ELEV) Given “Equal Weight” Rating at Stephens - Defense World
Analysts Set Expectations for ELEV FY2029 Earnings - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Neutral” at Piper Sandler - The AM Reporter
Massachusetts-Based Elevation Oncology Cuts 70% of Workforce After Drug Setback - NewsBreak: Local News & Alerts
Elevation Oncology (NASDAQ:ELEV) Rating Lowered to “Market Perform” at Citizens Jmp - Defense World
Elevation Oncology Inc (ELEV) 財務データ
収益
当期純利益
現金流量
EPS
0.85%
0.57%
大文字化:
|
ボリューム (24 時間):